Predict your next investment

Private Equity
frazierhealthcare.com

See what CB Insights has to offer

Investments

324

Portfolio Exits

95

Funds

15

Partners & Customers

5

Service Providers

3

About Frazier Healthcare Partners

Frazier Healthcare Partners was founded in 1991 as one of the first healthcare-focused investment firms. The firm has partnered with entrepreneurs in all stages of company growth, from company creation and venture capital to growth buyouts and leveraged recapitalizations. Frazier's experienced team takes an active approach to helping build portfolio companies, leveraging the team's deep domain expertise and expansive, global network of healthcare executives, advisors, and industry thought leaders.

Frazier Healthcare Partners Headquarter Location

Two Union Square 601 Union Street, Suite 3200

Seattle, Washington, 98101,

United States

206-621-7200

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Frazier Healthcare Partners

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Frazier Healthcare Partners in 1 CB Insights research brief, most recently on Mar 25, 2019.

Latest Frazier Healthcare Partners News

Frazier Healthcare Partners Announces Several Promotions; Adds Dr. Deneen Vojta as Senior Advisor

Jan 21, 2022

Frazier Healthcare Partners Announces Several Promotions; Adds Dr. Deneen Vojta as Senior Advisor SEATTLE, January 20, 2022-- Frazier Healthcare Partners, a leading healthcare investment firm, today announced several promotions on the Growth Buyout team and the addition of Dr. Deneen Vojta as Senior Advisor. We are pleased to announce the promotions of Clarissa Berman to Vice President and Michael Machak to Sr. Associate. Both joined the Frazier Growth Buyout IP team in 2019. Before Frazier, Ms. Berman worked at McKinsey and Company, and spent three years with Bauscher Brasil, a start-up she co-founded. Prior to founding Bauscher, Clarissa was a Vice President at Credit Suisse. Clarissa is a member of Frazier investment teams covering Effective School Solutions, EPTAM Precision, SunMed, and Vein Clinics of America. Mr. Machak was an investment banking analyst in the healthcare investment banking group at Raymond James in Nashville before joining Frazier as an Associate. Michael is a member of investment teams covering Accuity, Caravel, Parata Systems, and United Digestive. Additionally, Anup Gopalakrishnan, who joined the Frazier Center of Excellence team in 2020 as a Senior Director, Finance & Data Analytics, has been promoted to Partner. Mr. Gopalakrishnan most recently served as a consultant to healthcare companies focused on FP&A, mergers and acquisitions and finance processes. He was also previously the Chief Financial Officer at Alliant Health Solutions, a Medicare and Medicaid contractor of quality audit services, and before that he led the FP&A efforts at Healthcare Solutions which was acquired by Optum Rx. “We are thrilled with the promotions of Clarissa, Michael and Anup,” said Ben Magnano, Managing Partner. “Each of these individuals has made meaningful contributions to our firm’s success and we appreciate their continued dedication and commitment. We are proud to have such a talented team with diverse backgrounds, and we look forward to continuing to support the growth of all of our colleagues.” Finally, Frazier is delighted to announce the addition of Dr. Deneen Vojta as a Senior Advisor. Most recently, Dr. Vojta was Executive Vice President for Research and Development at UnitedHealth Group where she was responsible for building new businesses and creating innovative payment and delivery system frameworks. She was also the Founder and CEO of MYnetico, a digital weight management platform acquired by UNH in 2006. Earlier, she served as Chief Medical Officer of ARIA Health Care System and Health Partners of Philadelphia. She began her career by founding the nation’s first pediatric hospitalist program. We enthusiastically welcome Dr. Vojta to the Frazier family. About Frazier Healthcare Partners: Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With over $7 billion in total capital raised, Frazier has invested in more than 200 companies with transaction types ranging from buyouts of profitable healthcare services companies to venture capital and company creation. Frazier has a philosophy of partnering with strong management teams while leveraging its internal operating resources and network to build exceptional companies. Frazier has offices in Seattle, WA, and Menlo Park, CA, and invests broadly across the U.S., Canada, and Europe. For more information about Frazier Healthcare Partners, visit www.frazierhealthcare.com. Contact:

Frazier Healthcare Partners Investments

324 Investments

Frazier Healthcare Partners has made 324 investments. Their latest investment was in SanReno Therapeutics as part of their Series A on November 11, 2021.

CBI Logo

Frazier Healthcare Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/30/2021

Series A

SanReno Therapeutics

$40M

Yes

1

10/18/2021

Private Equity

Radionetics Oncology

$30M

Yes

1

10/15/2021

Series B - II

Scout Bio

$33M

No

4

9/8/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

8/4/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/30/2021

10/18/2021

10/15/2021

9/8/2021

8/4/2021

Round

Series A

Private Equity

Series B - II

Series A

Series B

Company

SanReno Therapeutics

Radionetics Oncology

Scout Bio

Subscribe to see more

Subscribe to see more

Amount

$40M

$30M

$33M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

4

10

10

Frazier Healthcare Partners Portfolio Exits

95 Portfolio Exits

Frazier Healthcare Partners has 95 portfolio exits. Their latest portfolio exit was Amunix on December 21, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/21/2021

Acquired

$99M

10

11/24/2021

IPO

2

7/16/2021

IPO

$99M

1

6/30/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

3/30/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/21/2021

11/24/2021

7/16/2021

6/30/2021

3/30/2021

Exit

Acquired

IPO

IPO

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

10

2

1

10

10

Frazier Healthcare Partners Acquisitions

18 Acquisitions

Frazier Healthcare Partners acquired 18 companies. Their latest acquisition was Accuity Delivery Systems on October 29, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/29/2020

Other

$99M

$69.46M

Acq - Fin

2

9/22/2020

$99M

Acq - Fin - III

1

5/5/2020

Series B

$99M

$97M

Acq - Fin

1/22/2020

Subscribe to see more

$99M

Subscribe to see more

10

10/10/2019

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/29/2020

9/22/2020

5/5/2020

1/22/2020

10/10/2019

Investment Stage

Other

Series B

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$69.46M

$97M

Note

Acq - Fin

Acq - Fin - III

Acq - Fin

Subscribe to see more

Subscribe to see more

Sources

2

1

10

10

Frazier Healthcare Partners Fund History

15 Fund Histories

Frazier Healthcare Partners has 15 funds, including Frazier Life Sciences Public Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

10/28/2021

Frazier Life Sciences Public Fund

$830M

1

5/27/2021

Frazier Healthcare Growth Buyout Fund X

$1,400M

1

1/16/2020

Frazier Life Sciences X

Early-Stage Venture Capital

Closed

$617M

2

4/10/2018

Frazier Healthcare Growth Buyout Fund XI

Subscribe to see more

Subscribe to see more

$99M

10

11/1/2017

Frazier Life Sciences IX

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

10/28/2021

5/27/2021

1/16/2020

4/10/2018

11/1/2017

Fund

Frazier Life Sciences Public Fund

Frazier Healthcare Growth Buyout Fund X

Frazier Life Sciences X

Frazier Healthcare Growth Buyout Fund XI

Frazier Life Sciences IX

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Amount

$830M

$1,400M

$617M

$99M

$99M

Sources

1

1

2

10

10

Frazier Healthcare Partners Partners & Customers

5 Partners and customers

Frazier Healthcare Partners has 5 strategic partners and customers. Frazier Healthcare Partners recently partnered with Takeda Pharmaceutical on July 7, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

7/30/2021

Licensor

Takeda Pharmaceutical

Japan

Takeda and Frazier to launch HilleVax for norovirus vaccine development

Meanwhile , Takeda Pharmaceutical and PeptiDream extended their research partnership and exclusive licence agreement to develop peptide-drug conjugates for various central nervous system targets , which play key roles in chronic neurodegenerative disorders .

2

5/16/2019

Partner

Takeda Pharmaceutical

Japan

Subscribe to see more

Subscribe to see more

10

2/6/2019

Partner

MicuRx Pharmaceuticals

United States

Subscribe to see more

Subscribe to see more

10

12/17/2018

Partner

Atlanta Gastroenterology Associates

United States

Subscribe to see more

Subscribe to see more

10

10/20/2016

Partner

The Providence Service Corporation

United States

Subscribe to see more

Subscribe to see more

10

Date

7/30/2021

5/16/2019

2/6/2019

12/17/2018

10/20/2016

Type

Licensor

Partner

Partner

Partner

Partner

Business Partner

Takeda Pharmaceutical

Takeda Pharmaceutical

MicuRx Pharmaceuticals

Atlanta Gastroenterology Associates

The Providence Service Corporation

Country

Japan

Japan

United States

United States

United States

News Snippet

Takeda and Frazier to launch HilleVax for norovirus vaccine development

Meanwhile , Takeda Pharmaceutical and PeptiDream extended their research partnership and exclusive licence agreement to develop peptide-drug conjugates for various central nervous system targets , which play key roles in chronic neurodegenerative disorders .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

10

Frazier Healthcare Partners Service Providers

3 Service Providers

Frazier Healthcare Partners has 3 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - Fin - II

Investment Bank

Financial Advisor, Sole Bookrunner, Sole Lead Arranger

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Acq - Fin - II

Provider Type

Investment Bank

Subscribe to see more

Subscribe to see more

Service Type

Financial Advisor, Sole Bookrunner, Sole Lead Arranger

Subscribe to see more

Partnership data by VentureSource

Frazier Healthcare Partners Team

21 Team Members

Frazier Healthcare Partners has 21 team members, including current President, Kelly McCullum.

Name

Work History

Title

Status

Kelly McCullum

President

Current

Steve Bailey

Chief Financial Officer

Current

Thomas S. Hodge

Chief Operating Officer

Current

Mohammad Mousa

Controller

Current

Alan Frazier

Managing Partner

Current

Name

Kelly McCullum

Steve Bailey

Thomas S. Hodge

Mohammad Mousa

Alan Frazier

Work History

Title

President

Chief Financial Officer

Chief Operating Officer

Controller

Managing Partner

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.